Mark Ng Tang Fui
Overview
Explore the profile of Mark Ng Tang Fui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grossmann M, Robledo K, Daniel M, Handelsman D, Inder W, Stuckey B, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39883545
No abstract available.
2.
Grossmann M, Robledo K, Daniel M, Handelsman D, Inder W, Stuckey B, et al.
J Clin Endocrinol Metab
. 2024 Feb;
109(8):2019-2028.
PMID: 38335137
Objective: To determine the effect of testosterone vs placebo treatment on health-related quality of life (HR-QOL) and psychosocial function in men without pathologic hypogonadism in the context of a lifestyle...
3.
Grossmann M, Fui M, Nie T, Hoermann R, Clarke M, Cheung A, et al.
Endocrine
. 2021 Apr;
73(2):463-471.
PMID: 33864607
Purpose: The aim of this study was to determine early weight loss-associated changes in subcutaneous abdominal white adipose tissue (WAT) gene expression in obese men with lowered serum testosterone by...
4.
Fui M, Hoermann R, Bracken K, Handelsman D, Inder W, Stuckey B, et al.
J Clin Endocrinol Metab
. 2021 Mar;
106(8):e3143-e3158.
PMID: 33693907
Context: Testosterone treatment increases bone mineral density (BMD) in hypogonadal men. Effects on bone microarchitecture, a determinant of fracture risk, are unknown. Objective: We aimed to determine the effect of...
5.
Wittert G, Bracken K, Robledo K, Grossmann M, Yeap B, Handelsman D, et al.
Lancet Diabetes Endocrinol
. 2020 Dec;
9(1):32-45.
PMID: 33338415
Background: Men who are overweight or obese frequently have low serum testosterone concentrations, which are associated with increased risk of type 2 diabetes. We aimed to determine whether testosterone treatment...
6.
Fui M, Hoermann R, Wittert G, Grossmann M
Asian J Androl
. 2019 Sep;
22(4):354-359.
PMID: 31535628
The aim of this study was to determine whether testicular volume is correlated with clinical and biochemical markers of hypothalamic-pituitary-testicular (HPT) axis function. This was a cross-sectional substudy of a...
7.
Hoermann R, Fui M, Krakauer J, Krakauer N, Grossmann M
Int J Obes (Lond)
. 2019 Jan;
43(11):2210-2216.
PMID: 30622310
Background: Interventions such as testosterone treatment may change body composition and metabolic outcomes without substantial changes in weight and BMI. Objectives: Using testosterone treatment as a paradigm, we hypothesized that...
8.
Fui M, Hoermann R, Nolan B, Clarke M, Zajac J, Grossmann M
Sci Rep
. 2018 Jun;
8(1):9099.
PMID: 29904126
To assess the effect of testosterone treatment on bone remodelling and density in dieting obese men, 100 obese men aged 53 years (interquartile range 47-60) with a total testosterone level...
9.
Fui M, Hoermann R, Grossmann M
J Endocr Soc
. 2017 Dec;
1(4):302-312.
PMID: 29264488
Context: In obese men with lowered testosterone levels, testosterone treatment augments diet-associated loss of body fat. Objective: We hypothesized that testosterone treatment modulates circulating concentrations of hormonal mediators of fat...
10.
Fui M, Hoermann R, Zajac J, Grossmann M
Clin Endocrinol (Oxf)
. 2017 Jun;
87(4):336-343.
PMID: 28561278
Background: Testosterone treatment in obese dieting men augments the diet-associated loss of fat mass, but protects against loss of lean mass. We assessed whether body composition changes are maintained following...